Rhino Therapeutics' mission is to translate compelling foundational science into transformative regenerative therapies for patients living with age-related olfactory loss, or presbyosmia, a highly prevalent disease of ageing associated with increased morbidity and 10-year mortality, and for which there are no approved therapies.  Our strategy seeks to exploit a deep understanding of pathology and molecular mechanisms that regulate the peripheral olfactory stem cell niche. 

Rhino Therapeutics, Inc is funded by Curie.Bio. For more information please visit https://curie.bio/